Boston Scientific Corporation

Equities

BSX

US1011371077

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 11:28:09 2024-04-24 am EDT 5-day change 1st Jan Change
73.44 USD +6.46% Intraday chart for Boston Scientific Corporation +7.86% +26.80%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
News Highlights : Top Company News of the Day - Wednesday at 11 AM ET DJ
The return of bad news is good news Our Logo
News Highlights : Top Company News of the Day - Wednesday at 9 AM ET DJ
Nasdaq, S&P futures advance on tech boost, earnings glee RE
Futures Mostly Rise in Premarket Ahead of More Corporate Earnings; Asia, Europe Up MT
Boston Scientific's Adjusted Q1 Earnings, Net Sales Rise; Q2, 2024 Outlook Issued, Shares Advance Pre-Bell MT
Boston Scientific Lifts 2024 Outlook After Strong 1Q DJ
Earnings Flash (BSX) BOSTON SCIENTIFIC CORPORATION Reports Q1 Revenue $3.86B, vs. Street Est of $3.68B MT
Boston Scientific Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Boston Scientific Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2024 CI
Edwards Lifesciences Corporation: The story continues Our Logo
Nephron Research Raises Boston Scientific's Price Target to $80 From $75 MT
FDA classifies recall of Boston Scientific device as 'most serious' RE
FDA classifies recall of Boston Scientific device to treat hemorrhaging as 'most serious' RE
Baird Adjusts Boston Scientific Price Target to $79 From $72 MT
Integer Holdings to Benefit from Pulsed Field Ablation Market Growth, BofA Says MT
Truist Securities Adjusts Boston Scientific Price Target to $79 From $73, Buy Rating Kept MT
BTIG Adjusts Boston Scientific's Price Target to $74 From $72 MT
RBC Raises Price Target on Boston Scientific to $78 From $70, Keeps Outperform Rating MT
Penumbra, Inc. : The underdog in healthcare Our Logo
Nectero Medical LLC announced that it has received $96 million in funding from Boston Scientific Corporation, NVP Associates, LLC, BioStar Ventures LLC, Cadence Healthcare Ventures, Llc, Aphelion Capital, LLC and other investors CI
Boston Scientific Starts Study of Software Module, Catheter for Treatment of Atrial Fibrillation MT
Boston Scientific, Axonics Receive FTC Second Request on Merger Deal MT
Boston Scientific, Axonics Merger Prompts FTC to Request Additional Information DJ
FTC seeks additional information for Boston Scientific's $3.7 bln Axonics deal RE
Chart Boston Scientific Corporation
More charts
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows: - cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%); - endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ; - neuromodulation (2%). The United States account for 59.2% of net sales.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
33
Last Close Price
68.99 USD
Average target price
73.4 USD
Spread / Average Target
+6.40%
Consensus